NEW YORK – Diagnostic firm Invitae and drug giant Pfizer recently launched a program to expand the availability of BRCA1/2 testing among breast cancer patients in six countries with otherwise limited access.
While the program may improve genetic testing access for inherited cancer risk, it still must operate within these countries' existing healthcare infrastructure. As such, patients may still lack access to the downstream screening and treatment interventions that may be indicated based on their genetic test results.